ENDARI Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ENDARI Growth

1. First new SCD therapy in nearly two decades (high unmet need)

• ENDARI was approved by the U.S. FDA in 2017, becoming the first new treatment for sickle cell disease (SCD) in almost 20 years.
• Prior to this, hydroxyurea was the only widely used therapy, leaving a major unmet need.

Impact:

• Being an early entrant with limited competition at launch enabled rapid initial adoption, especially in patients inadequately controlled on existing therapies.

2. Clinically validated reduction in vaso-occlusive crises and hospitalizations

• In a Phase III randomized trial (n=230), ENDARI demonstrated:
• 25% reduction in sickle cell crises
• 33% reduction in hospitalizations
• Significant reduction in cumulative hospital days and acute chest syndrome
• FDA data further confirms lower median crises (3 vs 4) and fewer hospital visits vs placebo.

Impact:

• Strong clinical benefit on hard endpoints (VOC + hospitalization) supports physician adoption and payer reimbursement.

3. Broad eligible patient population (pediatric + adult use)

• Approved for patients >=5 years, covering both pediatric and adult populations.
• SCD affects ~100,000 patients in the U.S. and millions globally.

Impact:

• Wide label enables large addressable population, supporting steady demand growth across age groups.

4. Favorable safety profile and oral administration advantage

• ENDARI is an oral amino acid therapy, unlike many newer biologics/gene therapies.
• Demonstrates a well-tolerated safety profile, with mostly mild adverse events (e.g., nausea, constipation).

5. Flexibility as monotherapy or combination therapy

• Updated FDA labeling confirms clinical benefit irrespective of hydroxyurea use.

Impact:

• Can be used:
• As add-on therapy (combination regimen)
• As alternative therapy in hydroxyurea-intolerant patients

> This flexibility expands utilization and supports long-term prescription volume growth.

6. Orphan drug incentives and regulatory support

• ENDARI received Orphan Drug designation, providing:
• Market exclusivity (until ~2024)
• Development incentives and regulatory support

ENDARI Recent Developments

• In January 2026, Emmaus Life Sciences Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, has granted NeoImmuneTech Inc. (NIT) an exclusive license to all rights to market, sell and distribute Endari (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a royalty on NIT's product sales.

"ENDARI Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ENDARI for approved indication like Short bowel syndrome and Sickle cell anaemia; as well as potential indication like Thalassaemia in the 7MM. A detailed picture of ENDARI's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ENDARI for approved and potential indications. The ENDARI market report provides insights about ENDARI's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ENDARI performance, future market assessments inclusive of the ENDARI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ENDARI sales forecasts, along with factors driving its market.

ENDARI Drug Summary

ENDARI is a prescription amino acid medication manufactured by Emmaus Medical, FDA-approved in 2017 as the first new sickle cell disease (SCD) treatment in nearly 20 years, indicated to reduce the frequency and severity of acute complications-such as vaso-occlusive pain crises-in adults and pediatric patients aged 5 years and older. The active ingredient, pharmaceutical-grade L-glutamine (5 g per packet), works by supporting antioxidant production in sickle-shaped red blood cells to mitigate oxidative stress, restore cell flexibility, and improve blood flow, though its precise mechanism remains incompletely understood. Administered orally twice daily-dosed by weight as 5 g (<30 kg), 10 g (30-65 kg), or 15 g (>65 kg), mixed in 8 oz of cold/room-temperature liquid (e.g., water, juice) or 4-6 oz of soft food (e.g., yogurt)-it is supplied in cartons of 60 single-dose packets and may cause common side effects like constipation, nausea, headache, abdominal pain, cough, and musculoskeletal pain. The report provides ENDARI's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ENDARI Market Report

The report provides insights into:

• A comprehensive product overview including the ENDARI MoA, description, dosage and administration, research and development activities in approved indications like Short bowel syndrome and Sickle cell anaemia; as well as potential indication like Thalassaemia.
• Elaborated details on ENDARI regulatory milestones and other development activities have been provided in ENDARI market report.
• The report also highlights ENDARI's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ENDARI market report also covers the patents information, generic entry and impact on cost cut.
• The ENDARI market report contains current and forecasted ENDARI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ENDARI market report also features the SWOT analysis with analyst views for ENDARI in approved and potential indications.

Methodology:

The ENDARI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ENDARI Analytical Perspective by DelveInsight

• In-depth ENDARI Market Assessment

This ENDARI sales market forecast report provides a detailed market assessment of ENDARI for approved indication like Short bowel syndrome and Sickle cell anaemia; as well as potential indication like Thalassaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ENDARI sales data uptil 2034.

• ENDARI Clinical Assessment

The ENDARI market report provides the clinical trials information of ENDARI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ENDARI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ENDARI Market Potential & Revenue Forecast

• Projected market size for the ENDARI and its key indications
• Estimated ENDARI sales potential (ENDARI peak sales forecasts)
• ENDARI Pricing strategies and reimbursement landscape

ENDARI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ENDARI Market positioning compared to existing treatments
• ENDARI Strengths & weaknesses relative to competitors

ENDARI Regulatory & Commercial Milestones

• ENDARI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ENDARI Clinical Differentiation

• ENDARI Efficacy & safety advantages over existing drugs
• ENDARI Unique selling points

ENDARI Market Report Highlights

• In the coming years, the ENDARI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ENDARI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ENDARI's dominance.
• Other emerging products for Short bowel syndrome and Sickle cell anaemia; as well as potential indication like Thalassaemia are expected to give tough market competition to ENDARI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ENDARI in approved and potential indications.
• Analyse ENDARI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ENDARI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ENDARI in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ENDARI? How strong is ENDARI's clinical and commercial performance?
• What is ENDARI's clinical trial status in each individual indications such as Short bowel syndrome and Sickle cell anaemia; as well as potential indication like Thalassaemia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ENDARI Manufacturers?
• What are the key designations that have been granted to ENDARI for approved and potential indications? How are they going to impact ENDARI's penetration in various geographies?
• What is the current and forecasted ENDARI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ENDARI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ENDARI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ENDARI? What is the duration of therapy and what are the geographical variations in cost per patient?